"2025 was transformational for Tonix as we achieved FDA approval and began the U.S. commercial launch of TONMYA, our first fully in-house developed product and the first new medicine approved for ...
These locally-owned restaurants represent some of Southerners' favorite places to eat across the region. These are the South's Best Classic Restaurants, as voted on by Southern Living readers.
(NYSE:JOBY), a company developing electric air taxis for commercial passenger service, today announced it has begun flight testing its first FAA-conforming aircraft for Type Inspection Authorization ...
Sir Ronnie Hampel, who has died aged 93, was one of the most successful and widely respected business leaders of his generation, rising to become chief executive and then chairman of ICI while ...
From The Sopranos to Seinfeld, the 1990s produced some of the most critically acclaimed television in history. We've ranked the top 15 TV shows that premiered in the '90s based on current IMDb user ...
Leading AI cloud company to build out presence in Asia-Pacific to tap region's growth potential Names John Haarer as General Manager for Asia-Pacific and Japan ...
The Company's third quarter reflected record service revenue driven by strong study execution and the conversion of previously booked work. As is typical in the Company's business, quarterly revenue ...
I’m feeling nostalgic this week, so we’re headed back to the 20th century to explore some of my favorite classic movies that are newly released this month on Amazon Prime Video. They became classics ...
BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA ...
Acorn Energy, Inc. (NASDAQ:ACFN) Q4 2025 Earnings Call Transcript March 5, 2026 Operator: Good morning, everyone, and welcome to Acorn Energy’s Fourth Quarter and Full Year 2025 Conference Call.
NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) ("NIO” or the "Company”), a pioneer and a leading company in the global smart el ...
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results